Solu Therapeutics

In April 2025, a patient with chronic myelomonocytic leukemia received the first dose of a drug called STX-0712. It was a quiet moment in a clinical trial - no press conference, no ribbon. But for Solu Therapeutics, it was the line between a promising idea on a whiteboard and a molecule moving through a human bloodstream.

Solu is a clinical-stage biotechnology company. That phrase covers a lot of hopeful companies. What separates this one is the bet underneath it: that you can fuse the surgical aim of a small molecule with the killing power of an antibody, and use the combination to hunt down the specific cells making someone sick.

Antibodies are the prestige players of modern medicine - precise, powerful, the backbone of a generation of blockbusters. They have one inconvenient habit: they only bind cleanly to a narrow set of cell-surface proteins. The richest targets in disease - G protein-coupled receptors and ion channels, with their deep, awkward binding pockets - mostly shrug antibodies off.

Small molecules, on the other hand, slip into those deep pockets with ease. What they lack is a way to translate "I found the bad cell" into "now kill it." For decades the two strengths sat in separate rooms, politely ignoring each other.

In 2023, the Longwood Fund - a Boston firm with a long habit of incubating biotechs - took an exclusive license to a platform called CyTAC out of GSK and stood up a company to run with it. David Donabedian came on as founding CEO, Brandon Turunen as the scientific co-founder, with Longwood's Christoph Westphal as founding executive chairman. The company later named Philip Vickers, a veteran drug developer, as President and CEO.

The bet was not subtle: take a piece of platform chemistry that a pharma giant had built but not prioritized, and pour a focused team into turning it into actual medicines. The seed round - an oversubscribed $31 million - suggested the bet had company.

Solu's core invention is a linker - a piece of chemistry that bolts a small-molecule binder onto an antibody, making one molecule that does two jobs. The first platform, CyTAC (Cytotoxicity Targeting Chimera), uses that trick to flag a pathogenic cell and recruit the immune machinery to destroy it. The second, TicTAC (Therapeutic Index Control Targeting Chimera), tunes a drug's behavior - pairing small-molecule agonists or antagonists with engineered antibodies to stretch how long it works and how cleanly.

Two rounds, $72 million, and a cap table that reads like a who's-who of people who do this for a living. The seed leaned on specialist biotech funds; the Series A added a pharma giant in Eli Lilly and, tellingly, a patient-advocacy investor - the Leukemia & Lymphoma Society - that only writes checks where it sees a path for patients.

Solu says it exists to develop a new generation of medicines that transform patient lives. Lots of companies say that. What gives it weight here is the spread: a blood cancer in the clinic, a mast-cell disease and an inflammatory condition in preclinical work, a pain program built on ion channels, and a prostate-cancer shot in discovery. The connective tissue isn't a single disease - it's a single trick, applied to targets that were supposed to be off-limits.

That focus on the platform, rather than any one drug, is the quiet strategy. If CyTAC and TicTAC work, the first approval is a proof point, not the finish line.

Return to April 2025 and the patient receiving the first dose of STX-0712. A year earlier, the deep-pocket target on those rogue monocytes - CCR2, a GPCR - would have been a line in a review paper titled "promising but hard to drug." Now it's the thing a molecule was designed to grab.

Solu hasn't cured anything yet. Phase 1 is early, biology is humbling, and most candidates don't make it. But the room has changed. A target that medicine had filed under "impossible" now has a drug walking toward it - and behind that drug, a platform built to do the same thing again, for the next target, and the one after that.